Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1050 Results

Intervention Indication Therapeutic Area Year Actions
Sotatercept for treating pulmonary arterial hypertension Sotatercep (ACE-011) Pulmonary arterial hypertension (PAH) Cardiovascular System , Respiratory System 2022 View  |  Download
Sparsentan for treating Focal Segmental Glomerulosclerosis Sparsentan (RE-021; PS433540) Focal segmental glomerulosclerosis (FSGS) Nephrology 2021 View  |  Download
Sparsentan for treating primary IgA nephropathy Sparsentan (RE-021; PS433540) IgA nephropathy Immunology , Nephrology 2023 View  |  Download
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2019 View  |  Download
Spesolimab for preventing generalised pustular psoriasis flares Spesolimab (BI 655130) Generalised pustular psoriasis flares Dermatology 2022 View  |  Download
Spesolimab for the treatment of acute flares of generalised pustular psoriasis Spesolimab (BI 655130) Generalised pustular psoriasis Dermatology 2021 View  |  Download
STS101 for the acute treatment of migraine STS-101 (TO-2070, dihydroergotamine) Migraine Neurology 2022 View  |  Download
Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Subcutaneous Tocilizumab (RoACTEMRA) With or Without Methotrexate for the Treatment of Inadequate Responders in Systemic Juvenile Idiopathic Arthritis Methotrexate (MTX; Otrexup; Vibex MTX; MQX-5902; methotrexate disodium; methotrexate sodium) , Tocilizumab (Actemra; R1569; RoActemra) Juvenile idiopathic arthritis Rheumatology 2017 View  |  Download
Sutimlimab for primary cold agglutinin disease Sutimlimab (BIVV009; TNT009) Cold agglutinin disease (CAD) Haematology , Immunology 2018 View  |  Download
1 2 87 88 89 90 91 104 105
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications